1. Bray, F. et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 68, 394–424. https://doi.org/10.3322/caac.21492 (2018).
2. Van Cutsem, E., Sagaert, X., Topal, B., Haustermans, K. & Prenen, H. Gastric cancer. Lancet 388, 2654–2664. https://doi.org/10. 1016/s0140-6736(16)30354-3 (2016).
3. Gravalos, C. & Jimeno, A. HER2 in gastric cancer: A new prognostic factor and a novel therapeutic target. Ann. Oncol. 19, 1523–1529. https://doi.org/10.1093/annonc/mdn169 (2008).
4. Slamon, D. J. et al. Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene. Sci- ence (New York, N.Y.) 235, 177–182. https://doi.org/10.1126/science.3798106 (1987).
5. Slamon, D. J. et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N. Engl. J. Med. 344, 783–792. https://doi.org/10.1056/nejm200103153441101 (2001).
6. Piccart-Gebhart, M. J. et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N. Engl. J. Med. 353, 1659–1672. https://doi.org/10.1056/NEJMoa052306 (2005).
7. Smith, I. et al. 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: A randomised controlled trial. Lancet 369, 29–36. https://doi.org/10.1016/s0140-6736(07)60028-2 (2007).
8. Ross, J. S. et al. The HER-2 receptor and breast cancer: Ten years of targeted anti-HER-2 therapy and personalized medicine. Oncologist 14, 320–368. https://doi.org/10.1634/theoncologist.2008-0230 (2009).
9. Bang, Y. J. et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): A phase 3, open-label, randomised controlled trial. Lancet 376, 687–697. https://doi.org/10.1016/S0140-6736(10)61121-X (2010).
10. Berns, K. et al. A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer. Cancer Cell 12, 395–402. https://doi.org/10.1016/j.ccr.2007.08.030 (2007).
11. Nahta, R., Yu, D., Hung, M. C., Hortobagyi, G. N. & Esteva, F. J. Mechanisms of disease: Understanding resistance to HER2-targeted therapy in human breast cancer. Nat. Clin. Pract. Oncol. 3, 269–280. https://doi.org/10.1038/ncponc0509 (2006).
12. Nagata, Y. et al. PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resist- ance in patients. Cancer Cell 6, 117–127. https://doi.org/10.1016/j.ccr.2004.06.022 (2004).
13. Deguchi, Y. et al. PTEN loss is associated with a poor response to trastuzumab in HER2-overexpressing gastroesophageal adeno- carcinoma. Gastric Cancer 20, 416–427. https://doi.org/10.1007/s10120-016-0627-z (2017).
14. Lee, J. J., Loh, K. & Yap, Y. S. PI3K/Akt/mTOR inhibitors in breast cancer. Cancer Biol. Med. 12, 342–354. https://doi.org/10.7497/j. issn.2095-3941.2015.0089 (2015).
15. Pohlmann, P. R., Mayer, I. A. & Mernaugh, R. Resistance to trastuzumab in breast cancer. Clin. Cancer Res. 15, 7479–7491. https:// doi.org/10.1158/1078-0432.CCR-09-0636 (2009).
16. McKenna, M., McGarrigle, S. & Pidgeon, G. P. The next generation of PI3K-Akt-mTOR pathway inhibitors in breast cancer cohorts. Biochim. Biophys. Acta Rev. Cancer 1870, 185–197. https://doi.org/10.1016/j.bbcan.2018.08.001 (2018).
17. Andre, F. et al. Everolimus for women with trastuzumab-resistant, HER2-positive, advanced breast cancer (BOLERO-3): A ran- domised, double-blind, placebo-controlled phase 3 trial. Lancet Oncol. 15, 580–591. https://doi.org/10.1016/S1470-2045(14)70138- X (2014).
18. Ohtsu, A. et al. Everolimus for previously treated advanced gastric cancer: Results of the randomized, double-blind, phase III GRANITE-1 study. J. Clin. Oncol. 31, 3935–3943. https://doi.org/10.1200/JCO.2012.48.3552 (2013).
19. Eisenhauer, E. A. et al. New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur. J. Cancer 45, 228–247. https://doi.org/10.1016/j.ejca.2008.10.026 (2009).
20. Pietrantonio, F. et al. Biomarkers of primary resistance to trastuzumab in HER2-positive metastatic gastric cancer patients: The AMNESIA case–control study. Clin. Cancer Res. 24, 1082–1089. https://doi.org/10.1158/1078-0432.Ccr-17-2781 (2018).
21. Kim, C. et al. PTEN loss and level of HER2 amplification is associated with trastuzumab resistance and prognosis in HER2-positive gastric cancer. Oncotarget 8, 113494–113501. https://doi.org/10.18632/oncotarget.23054 (2017).
22. Zhang, X. et al. PTEN deficiency as a predictive biomarker of resistance to HER2-targeted therapy in advanced gastric cancer. Oncology 88, 76–85. https://doi.org/10.1159/000366426 (2015).
23. Bazzichetto, C. et al. PTEN as a prognostic/predictive biomarker in cancer: An unfulfilled promise?. Cancer 11, 435. https://doi. org/10.3390/cancers11040435 (2019).
24. Ramanathan, R. K. et al. Phase 2 study of MK-2206, an allosteric inhibitor of AKT, as second-line therapy for advanced gastric and gastroesophageal junction cancer: A SWOG cooperative group trial (S1005). Cancer 121, 2193–2197. https://doi.org/10.1002/ cncr.29363 (2015).
25. Hudis, C. A. Trastuzumab—Mechanism of action and use in clinical practice. N. Engl. J. Med. 357, 39–51. https://doi.org/10.1056/ NEJMra043186 (2007).
26. Valabrega, G., Montemurro, F. & Aglietta, M. Trastuzumab: Mechanism of action, resistance and future perspectives in HER2- overexpressing breast cancer. Ann. Oncol. 18, 977–984. https://doi.org/10.1093/annonc/mdl475 (2007).
27. Fan, J. P., Qian, J. & Zhao, Y. J. The loss of PTEN expression and microsatellite stability (MSS) were predictors of unfavorable prognosis in gastric cancer (GC). Neoplasma https://doi.org/10.4149/neo_2020_200422N427 (2020).
28. Rozengurt, E., Soares, H. P. & Sinnet-Smith, J. Suppression of feedback loops mediated by PI3K/mTOR induces multiple over- activation of compensatory pathways: An unintended consequence leading to drug resistance. Mol. Cancer Ther. 13, 2477–2488. https://doi.org/10.1158/1535-7163.MCT-14-0330 (2014).
29. Zhu, Y. et al. Dual PI3K/mTOR inhibitor BEZ235 exerts extensive antitumor activity in HER2-positive gastric cancer. BMC Cancer 15, 894. https://doi.org/10.1186/s12885-015-1900-y (2015).
30. Ecker, B. L. et al. HER3 expression is a marker of tumor progression in premalignant lesions of the gastroesophageal junction. PLoS ONE 11, e0161781. https://doi.org/10.1371/journal.pone.0161781 (2016).
31. Karamouzis, M. V., Badra, F. A. & Papavassiliou, A. G. Breast cancer: The upgraded role of HER-3 and HER-4. Int. J. Biochem. Cell Biol. 39, 851–856. https://doi.org/10.1016/j.biocel.2006.11.017 (2007).
32. Lee, H. E. et al. Clinical significance of intratumoral HER2 heterogeneity in gastric cancer. Eur. J. Cancer 49, 1448–1457. https:// doi.org/10.1016/j.ejca.2012.10.018 (2013).
33. Kurokawa, Y. et al. Multicenter large-scale study of prognostic impact of HER2 expression in patients with resectable gastric cancer. Gastric Cancer 18, 691–697. https://doi.org/10.1007/s10120-014-0430-7 (2015).
34. Kim, K. C. et al. Evaluation of HER2 protein expression in gastric carcinomas: Comparative analysis of 1,414 cases of whole-tissue sections and 595 cases of tissue microarrays. Ann. Surg. Oncol. 18, 2833–2840. https://doi.org/10.1245/s10434-011-1695-2 (2011).
35. Nishida, Y. et al. A novel gene-protein assay for evaluating HER2 status in gastric cancer: Simultaneous analyses of HER2 protein overexpression and gene amplification reveal intratumoral heterogeneity. Gastric Cancer 18, 458–466. https://doi.org/10.1007/ s10120-014-0394-7 (2015).
36. Wakatsuki, T. et al. Clinical impact of intratumoral HER2 heterogeneity on trastuzumab efficacy in patients with HER2-positive gastric cancer. J. Gastroenterol. 53, 1186–1195. https://doi.org/10.1007/s00535-018-1464-0 (2018).
37. Bettstetter, M. et al. Epidermal growth factor receptor, phosphatidylinositol-3-kinase catalytic subunit/PTEN, and KRAS/NRAS/ BRAF in primary resected esophageal adenocarcinomas: Loss of PTEN is associated with worse clinical outcome. Hum. Pathol. 44, 829–836. https://doi.org/10.1016/j.humpath.2012.08.005 (2013).